Skip to main content
. Author manuscript; available in PMC: 2023 Dec 14.
Published in final edited form as: Psychopharmacology (Berl). 2008 Jun 22;200(1):39–50. doi: 10.1007/s00213-008-1097-8

Fig. 4.

Fig. 4

There was no difference in the number of trials required to reach criterion performance on Rev3 or the test of learned irrelevance regardless of the dose of atomoxetine these rats received. These data show the selective benefit of these doses of atomoxetine on attentional set shifting without changes in other aspects of cognitive testing